State Street SPDR MSCI Europe Health Care UCITS ETF
STW.PA
Euronext Paris- -
EUR
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- SPDR MSCI Europe Health Care UCITS ETF (STW.PA) is an exchange-traded fund that seeks to replicate, before fees and expenses, the performance of the MSCI Europe Health Care Index, which tracks the performance of large- and mid-capitalization companies in the health care sector across developed European markets. The fund primarily invests in a portfolio of equity securities comprising pharmaceutical companies, biotechnology firms, health care equipment and supplies providers, and health care providers; it employs a full replication strategy by holding all index constituents in substantially the same weightings as the underlying benchmark. Domiciled in Ireland and listed on Euronext Paris under ticker STW.PA, the ETF was launched in 2013 and is managed by State Street Global Advisors (SSGA), a subsidiary of State Street Corporation headquartered in Boston, Massachusetts, with primary operations in Europe facilitated through its Luxembourg and Irish entities. Geographically, the fund focuses on European countries including the United Kingdom, Switzerland, Germany, France, and Denmark, targeting institutional and retail investors seeking exposure to Europe's health care industry, which includes major players like Novo Nordisk, AstraZeneca, Roche Holding, and Sanofi. Recent developments include enhancements to the fund's liquidity profile amid increased European ETF inflows in 2024-2025, driven by sector resilience in pharmaceuticals and biotech amid global health care demand; SSGA announced portfolio optimizations in late 2024 to align with updated MSCI index methodology changes incorporating ESG factors more prominently, alongside a strategic alliance with Euronext for improved trading efficiency on Paris; no major acquisitions or rebranding occurred, but the fund benefited from a 2025 capital inflow surge following strong health care sector performance during economic uncertainties.